The TRPV4-TAZ mechanotransduction signaling axis in matrix stiffness- and TGFβ1-induced epithelial-mesenchymal transition.
Smad2/3
TAZ
TRPV4
epithelial-mesenchymal transition
fibrosis
keratinocytes
matrix stiffness
Journal
Cellular and molecular bioengineering
ISSN: 1865-5025
Titre abrégé: Cell Mol Bioeng
Pays: United States
ID NLM: 101468590
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
pmc-release:
11
12
2019
entrez:
5
11
2019
pubmed:
5
11
2019
medline:
5
11
2019
Statut:
ppublish
Résumé
The implantation of biomaterials into soft tissue leads to the development of foreign body response, a non-specific inflammatory condition that is characterized by the presence of fibrotic tissue. Epithelial-mesenchymal transition (EMT) is a key event in development, fibrosis, and oncogenesis. Emerging data support a role for both a mechanical signal and a biochemical signal in EMT. We hypothesized that transient receptor potential vanilloid 4 (TRPV4), a mechanosensitive channel, is a mediator of EMT. Normal human primary epidermal keratinocytes (NHEKs) were seeded on collagen-coated plastic plates or varied stiffness polyacrylamide gels in the presence or absence of TGFβ1, Immunofluorescence, immunoblot, and polymerase chain reaction analysis were performed to determine expression level of EMT markers and signaling proteins. Knock-down of TRPV4 function was achieved by siRNA transfection or by GSK2193874 treatment. We found that knock-down of TRPV4 blocked both matrix stiffness- and TGFβ1-induced EMT in NHEKs. In a murine skin fibrosis model, TRPV4 deletion resulted in decreased expression of the mesenchymal marker, α-SMA, and increased expression of epithelial marker, E-cadherin. Mechanistically, our data showed that: i) TRPV4 was essential for the nuclear translocation of TAZ in response to matrix stiffness and TGFβ1; ii) Antagonism of TRPV4 inhibited both matrix stiffness-induced and TGFβ1-induced expression of TAZ proteins; and iii) TRPV4 antagonism suppressed both matrix stiffness-induced and TGFβ1-induced activation of Smad2/3, but not of AKT. These data identify a novel role for TRPV4-TAZ mechanotransduction signaling axis in regulating EMT in NHEKs in response to both matrix stiffness and TGFβ1.
Identifiants
pubmed: 31681446
doi: 10.1007/s12195-018-00565-w
pmc: PMC6816769
mid: NIHMS1516414
pii: 565
doi:
Types de publication
Journal Article
Langues
eng
Pagination
139-152Subventions
Organisme : NIBIB NIH HHS
ID : R01 EB024556
Pays : United States
Déclaration de conflit d'intérêts
Conflicts of interest: Shweta Sharma, Rishov Goswami, and Shaik O. Rahaman declare that they have no conflicts of interest.
Références
Nat Mater. 2014 Oct;13(10):918-20
pubmed: 25241671
Am J Pathol. 2004 Dec;165(6):1955-67
pubmed: 15579439
J Invest Dermatol. 2012 Apr;132(4):1253-62
pubmed: 22189789
Proc Natl Acad Sci U S A. 2013 Aug 20;110(34):E3225-34
pubmed: 23929777
Mol Oncol. 2015 Jun;9(6):1091-105
pubmed: 25704916
Respir Res. 2015 May 27;16:60
pubmed: 26006045
Handb Exp Pharmacol. 2014;222:293-319
pubmed: 24756711
Science. 2005 Nov 18;310(5751):1139-43
pubmed: 16293750
Nat Cell Biol. 2015 May;17(5):678-88
pubmed: 25893917
J Clin Med. 2016 Feb 19;5(2):
pubmed: 26907357
Handb Exp Pharmacol. 2007;(179):189-205
pubmed: 17217058
J Biol Chem. 2016 May 6;291(19):10252-62
pubmed: 26961876
Commun Integr Biol. 2010 Nov;3(6):619-21
pubmed: 21331258
Pflugers Arch. 2012 Apr;463(5):715-25
pubmed: 22374181
Exp Cell Res. 2012 Sep 10;318(15):1926-32
pubmed: 22664326
PLoS One. 2015 Jul 28;10(7):e0134092
pubmed: 26217927
Curr Opin Rheumatol. 2013 Jan;25(1):92-100
pubmed: 23114589
Exp Dermatol. 2014 Jul;23(7):497-503
pubmed: 24848428
Sci Rep. 2016 Oct 24;6:35696
pubmed: 27774992
Expert Rev Respir Med. 2014 Oct;8(5):547-59
pubmed: 25113142
J Biol Chem. 2003 Jun 6;278(23):21113-23
pubmed: 12665527
J Cell Sci. 2007 May 15;120(Pt 10):1801-9
pubmed: 17456553
Physiology (Bethesda). 2013 Nov;28(6):380-90
pubmed: 24186933
J Cell Physiol. 2011 May;226(5):1248-54
pubmed: 20945383
Arch Dermatol Res. 2012 Oct;304(8):589-97
pubmed: 22886298
Nat Cell Biol. 2008 Jul;10(7):837-48
pubmed: 18568018
Cell. 2013 Aug 29;154(5):1047-1059
pubmed: 23954413
Am J Physiol Lung Cell Mol Physiol. 2011 Jun;300(6):L887-97
pubmed: 21441353
Sci Rep. 2016 Jan 05;6:18831
pubmed: 26728047
Oncogenesis. 2017 Jul 3;6(7):e352
pubmed: 28671675
Nat Rev Mol Cell Biol. 2014 Dec;15(12):802-12
pubmed: 25355505
J Clin Invest. 2014 Dec;124(12):5225-38
pubmed: 25365224
Nature. 2011 Jun 08;474(7350):179-83
pubmed: 21654799
Am J Physiol Gastrointest Liver Physiol. 2007 Dec;293(6):G1147-54
pubmed: 17932231
Mol Biol Cell. 2013 Nov;24(21):3326-36
pubmed: 24006486
Am J Pathol. 2010 Oct;177(4):1743-54
pubmed: 20709799
Res Rep Health Eff Inst. 2014 Nov;(182):3-41
pubmed: 25669020
Cells Tissues Organs. 2005;179(1-2):11-23
pubmed: 15942189
J Biol Chem. 2003 Jun 20;278(25):22664-8
pubmed: 12692122
Sci Rep. 2017 Feb 14;7:42595
pubmed: 28195168
J Am Soc Nephrol. 2016 Oct;27(10):3117-3128
pubmed: 26961347
Cell Res. 2009 Feb;19(2):156-72
pubmed: 19153598
Am J Physiol Cell Physiol. 2017 May 1;312(5):C562-C572
pubmed: 28249987
Oncogene. 2012 Apr 5;31(14):1743-56
pubmed: 21874053
J Clin Invest. 2009 Jun;119(6):1429-37
pubmed: 19487819
Sci Rep. 2016 Mar 24;6:23269
pubmed: 27011063
Hypertension. 2009 Mar;53(3):532-8
pubmed: 19188524
Nat Rev Cancer. 2008 May;8(5):361-75
pubmed: 18432251
Front Med (Lausanne). 2015 Sep 03;2:59
pubmed: 26389119
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
J Invest Dermatol. 1999 Apr;112(4):456-62
pubmed: 10201529
Am J Respir Cell Mol Biol. 2015 Aug;53(2):135-48
pubmed: 25785898
Cell Cycle. 2012 Aug 1;11(15):2922-30
pubmed: 22825057
J Mol Cell Cardiol. 2013 Jan;54:45-52
pubmed: 23142541
J Biol Chem. 2017 Sep 8;292(36):14902-14920
pubmed: 28739802
J Cell Biol. 2007 Dec 17;179(6):1311-23
pubmed: 18086923
Am J Physiol Cell Physiol. 2014 Jun 1;306(11):C1050-7
pubmed: 24671100
Am J Physiol Lung Cell Mol Physiol. 2015 Feb 15;308(4):L344-57
pubmed: 25502501
Mol Med Rep. 2015 Feb;11(2):982-8
pubmed: 25354978
Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2708-18
pubmed: 17525203
Nat Mater. 2014 Oct;13(10):970-8
pubmed: 24930031
Am J Physiol Lung Cell Mol Physiol. 2015 Oct 15;309(8):L756-67
pubmed: 26320155
Nat Rev Mol Cell Biol. 2003 Jul;4(7):517-29
pubmed: 12838335
Cancer Res. 2008 Feb 1;68(3):937-45
pubmed: 18245497
Mol Cell Biol. 2008 Apr;28(7):2426-36
pubmed: 18227151
Sci Rep. 2017 Jun 14;7(1):3486
pubmed: 28615628
Mol Biol Cell. 2012 Mar;23(5):781-91
pubmed: 22238361
Cell Motil Cytoskeleton. 2005 Jan;60(1):24-34
pubmed: 15573414
Med Oncol. 2013;30(2):566
pubmed: 23572150
Prog Biophys Mol Biol. 2010 Sep;103(1):2-17
pubmed: 19835908
Part Fibre Toxicol. 2016 Jun 01;13(1):27
pubmed: 27251132
Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):19084-9
pubmed: 20956320
Cancer Cell. 2005 Sep;8(3):241-54
pubmed: 16169468
Int J Biochem Cell Biol. 2012 May;44(5):728-32
pubmed: 22387568
Cell Tissue Res. 2016 Sep;365(3):495-506
pubmed: 27461257
Am J Respir Cell Mol Biol. 1995 Jul;13(1):34-44
pubmed: 7541221
J Invest Dermatol. 2017 Apr;137(4):962-965
pubmed: 27889423
J Biol Chem. 2000 Nov 24;275(47):36803-10
pubmed: 10969078
J Am Soc Nephrol. 2016 Oct;27(10):3063-3078
pubmed: 26940090
Oncogene. 2014 May 1;33(18):2307-16
pubmed: 23686305
Sci Transl Med. 2012 Nov 7;4(159):159ra148
pubmed: 23136043
Am J Respir Crit Care Med. 2009 Oct 1;180(7):657-65
pubmed: 19556518
Toxicol Appl Pharmacol. 2014 Jun 15;277(3):250-8
pubmed: 24726524
J Clin Med. 2015 Dec 30;5(1):
pubmed: 26729181
Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15623-8
pubmed: 18832165
J Pathol. 2013 Jan;229(1):25-35
pubmed: 23018598
Am J Respir Crit Care Med. 2009 Jul 15;180(2):122-33
pubmed: 19406982
Proc Natl Acad Sci U S A. 2017 Jan 17;114(3):492-497
pubmed: 28034921
J Physiol. 2017 May 15;595(10):3063-3075
pubmed: 28304082
Mol Oncol. 2016 Jan;10(1):166-78
pubmed: 26433470
J Cell Physiol. 2015 Aug;230(8):1829-39
pubmed: 25522130
Mol Biol Rep. 2012 Apr;39(4):3549-56
pubmed: 21713404